DiaSorin S.R.L. Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 4/6/2026)
| Balance Sheet | Total Assets | 2,873,160,000.00 | ROE | 55.15 % |
| Balance Sheet | Total Equity | 1,584,490,000.00 | ROA | 5.42 % |
| Cashflow | Capital Expenditures | -137,681,000.00 | P/FCF | 20.28 |
| Cashflow | Free Cash Flow | 205,079,008.00 | – | – |
| Cashflow | Operating Cash Flow | 342,760,000.00 | P/CF | 12.14 |
| Income | Earnings per Share (diluted) | 2.94 | Div. Yield | 1.66 % |
| Income | Net Income | 155,624,000.00 | P/E | 26.69 |
| Income | Shares Outstanding | 53,000,700.00 | P/B | 2.63 |
| Income | Total Revenue | 1,195,050,000.00 | P/S | 3.48 |
Ratios calculated on: 10/14/2026
Company Description
DiaSorin S.p.A. engages in the development, production, and commercialization of diagnostic tests that are designed for hospital and private testing laboratories for use in various clinical areas in the market of immunodiagnostics and molecular diagnostics. The company offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; stool diagnostics; autoimmunity; and cardiac and brain damages. Its immunodiagnostics systems include LIAISON XL, an automated chemiluminescence analyzer; LIAISON analyzer; EVOlyzer 2-150/8 with disposable tips; and ETI Max 3000, an automated microtiter plate analyzer. The company also offers molecular diagnostic products for oncology, hematology, and infectious diseases; systems, including BULLET Pro and LIAISON Ixt to extract the nucleic acid from various biological samples; and LIAISON Iam to diagnose and various infectious diseases and onco-hematology parameters. It sells its products directly, as well as through an international network of independent distributors in Europe, Africa, Central America, South America, the Asia Pacific, and North America. DiaSorin S.p.A. was founded in 1968 and is headquartered in Saluggia, Italy.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.diasorin.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more